April 2012

ADHD Medications and Cardiovascular Risk
A large study of adults with attention-deficit/hyperactivity disorder (ADHD) found no link between ADHD medications and increased risk for adverse cardiovascular events.

High-Dose Quetiapine
Dosages of quetiapine (Seroquel) greater than the recommended maximum of 800 mg/day are unlikely to increase clinical benefit.

Armodafinil: A Negative Study for Negative Symptoms
Adding armodafinil to antipsychotic treatment did not improve negative symptoms in patients with schizophrenia.

In Brief
Care for Prisoners with Dementia Is an Growing Dilemma

SSRIs and Falls in Dementia Patients
In a study in the Netherlands, the use of selective-serotonin reuptake inhibitors (SSRIs) by nursing home residents with dementia increased the risk of injurious falls in a dose-dependent fashion.

Exercise Decreases Depressive Symptoms in Chronic Illness
A literature review of studies of exercise training concluded that exercise significantly reduces depressive symptoms in chronically ill patients.

ADHD Medications and Cardiovascular Risk

April 2012

We recently reviewed a study that concluded that drugs used for the treatment of attention-deficit/hyperactivity disorder (ADHD) did not present a substantial risk of adverse cardiovascular events for children and young adults (BTP 2012;33:8).1 A similar conclusion concerning middle-aged…

To view the rest of this article, please: